Barclays Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $26.00

Intellia Therapeutics (NASDAQ:NTLA) had its price objective cut by research analysts at Barclays from $55.00 to $26.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 157.68% from the stock’s current price.

A number of other equities analysts have also weighed in on NTLA. Chardan Capital decreased their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $56.00 to $11.00 in a research report on Monday, January 27th. Wells Fargo & Company cut their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday. Wedbush reissued a “neutral” rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.12.

Intellia Therapeutics Stock Down 7.1 %

Shares of Intellia Therapeutics stock traded down $0.77 on Friday, reaching $10.09. The company’s stock had a trading volume of 4,574,403 shares, compared to its average volume of 3,292,689. Intellia Therapeutics has a 52 week low of $8.96 and a 52 week high of $34.87. The firm’s fifty day simple moving average is $10.90 and its two-hundred day simple moving average is $15.72. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 29,000 shares of company stock worth $352,551 over the last quarter. Insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in Intellia Therapeutics in the fourth quarter valued at about $25,000. Sterling Capital Management LLC increased its holdings in shares of Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in shares of Intellia Therapeutics in the 4th quarter valued at approximately $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics in the 4th quarter worth approximately $43,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after purchasing an additional 794 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.